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Supplementary Methods 
 
Analysis of Public Datasets  
A dataset containing mRNA expression of 41 breast cancer cell lines1 was used for mRNA 
expression analysis of GPT2. Cell lines were classified into luminal and basal according to their 
molecular characteristics2. Publicly available data from the Molecular Taxonomy of Breast 
Cancer International Consortium3 (METABRIC) was analyzed with regard to gene expression 
and clinical characteristics of primary breast cancer tumors. Publicly available RNA-
sequencing data and clinical annotations from The Cancer Genome Atlas4 (TCGA) were 
analyzed from primary breast cancer tumors. Level 3 normalized gene expression data 
(TCGA_BRCA_exp_HiSeqV2-2015-02-24) was obtained from the cBioPortal website5,6. Gene 
expression data was log2 transformed and subset to the genes of interest. Patient data were 
subjected to Kaplan-Meier analysis of overall survival (OS) and recurrence-free survival (RFS). 
Differences of Kaplan-Meier curves were statistically tested using the log-rank test. Differences 
between subgroups depicted in the boxplots were analyzed with ANOVA and significance was 
calculated with Bonferroni’s Multiple Comparison Test. Data was analyzed using GraphPad 
Prism 5 (La Jolla, CA, USA) or the R statistical computing environment7 (version 3.2.2).  
Alanine Assay  
GPT2 inhibitor (BCLA) inhibitor titration was done by measuring the alanine levels in the 
supernatant using the alanine assay kit from Sigma. To analyze alanine levels supernatant was 
diluted 1:10 and 5μl of the diluted media was used in the assay according to manufacturer’s 
instructions.  
mTORC1 activity assay  
Cells were seeded to 80% confluency. After overnight incubation cells were starved (with 
media containing 0.1% serum) for 24 h. The following day starvation media was replaced with 
amino acid free media (RPMI 1640 media w/o amino acids, US Biologicals, Salem, USA, and 
10% Dialyzed Fetal Bovine serum, Thermo Fisher Scientific, Waltham, USA) for 50 min 
following by replacement with regular media. Protein lysates were harvested after 5, 10, 15, 30 
and 45 min and analyzed by immunoblotting.  
Hematoxylin/eosin staining and immunohistochemistry of mouse tumor tissues  
Five μm sections of paraffin-embedded tumors were used for routine hematoxylin/eosin (HE) 
staining. p62 was detected in de-paraffinized tissue specimens after antigen retrieval (10 min 
and 20 min, respectively at boiling temperature in 10 mM sodium citrate pH 6.0), block of 
endogenous peroxidases in 3% H2O2 in PBS for 10 min, blocking in 100% goat serum for 1 h 
at room temperature (RT) and overnight incubation at 4° C in anti-p62 antibody (1:600; GP62-
C Progen, Heidelberg, Germany). Slides, incubated with appropriate peroxidase-coupled 
secondary antibody (1:200) for 1h at RT, were incubated with HRP substrate solution 
(DAB/H2O2, Sigma Aldrich, Munich, Germany). Nuclei were counterstained with 
hematoxylin for 1 min and mounted with Eukitt (R. Langenbrinck, Teningen, Germany). 
Sections incubated without primary antibody were included as negative controls. Microscopy 
was performed using Axioskop 2 microscope and Axiovision software (Carl Zeiss, Gottingen, 
Germany).  
Mouse tumor tissue metabolite measurements  
Extraction  
Mouse tumor tissues were ground with 7 mm steel bead in a 2 mL centrifuge tube with 20Hz 
for 60-90 sec in a Retsch mill (Retsch GmbH, NRW, Germany) and extracted in 180 μL of 
100% methanol for 15 min at 70° C with vigorous shaking. As internal standard 5 μL Ribitol 
(0.2 mg/mL) were added to each sample. After the addition of 100 μL chloroform, samples 
were shaken at 37° C for 5 min. To separate polar and organic phases, 200 μL of water were 
added and samples were centrifuged for 10 min at 16,000 x g. For derivatization, 300 μL of the 
polar (upper) phase were transferred to a fresh tube and dried in a vacuum concentrator without 
heating. Amino acids were measured in the polar phase using the UPLC analysis (method in 
section extracellular metabolite measurements).  
Derivatization (Methoximation and Silylation)  
Pellets were re-dissolved in 20 μL methoximation reagent containing 20 mg/mL methoxyamine 
hydrochloride (Sigma-Aldrich, Saint-Louis, USA, 226904) in pyridine (Sigma-Aldrich, Saint-
Louis, USA, 270970) and incubated for 2 h at 37° C with shaking. For silylation, 32.2 μL N-
Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA; Sigma-Aldrich, Saint-Louis, USA 
M7891) and 2.8 μL Alkane Standard Mixture (50 mg/mL C10 - C40; Sigma-Aldrich, Saint-
Louis, USA, 68281) were added to each sample. After incubation for 45 min at 50° C, samples 
were transferred to glass vials for GC/MS analysis.  
Gas Chromatography/Mass Spectrometry (GC/MS) analysis  
A GC/MS-QP2010 Plus (Shimadzu, Kyoto, Japan) fitted with a Zebron ZB 5MS column 
(Phenomenex, Torrence, USA; 30 meter x 0.25 mm x 0.25 μm) was used for GC/MS analysis. 
The GC was operated with an injection temperature of 230° C and 1 μL sample was injected 
with split mode (1:5). The GC temperature program started with a 1 min hold at 40° C followed 
by a 6° C/min ramp to 210° C, a 20° C/min ramp to 330° C and a bake-out for 5 min at 330° C, 
using Helium as carrier gas with constant linear velocity. The MS was operated with ion source 
and interface temperatures of 250° C, a solvent cut time of 8.0 min and a scan range (m/z) of 
40 – 700 with an event time of 0.2 s. The “GCMS solution” software (Shimadzu, Kyoto, Japan) 
was used for data processing.  
*Reference numbers correspond to references in the main manuscript file 
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Supplementary Table 1: siRNA used in this study 



































siPC#1 Dharmacon D-008950-18 GGAUAAUGCUUCCGCCUUC 
siPC#2 Dharmacon D-008950-19 UCUCUGAGCGAGCGGACUU 
 
  
Supplementary Table 2: sgRNAs used in this study  
sgRNA Supplier Sequence Target 
Exon 
Target 
sgRNA 1 Synthego 
Corporation 
GUGCAUAGUGCCAUCACCUG 4 46900682 
sgRNA2 Synthego 
Corporation 
UGUCUUGUUCCCCCAGGUGA 4 46900683 
Supplementary Table 3: Primers and probes used in this study  
Gene Supplier Primer Left Primer Right UPL Probe 
# 
GPT1 Roche gggaaggcacctaccacttc ttggcatggaacctgctc 66 
GPT2 Roche  ggatcttcattcctgccaaa acatgtctggagccatttga 75 
PC Roche agcaagctcttcagcatgg aggggcactcatacaggaag 52 
PUM1 Roche tcacatggatcctcttcaagc cctggagcagcagagatgtat 86 
Supplementary Table 4: Primary antibodies used in this study  
Protein name Host Product ID Product ID 
(Company) 
     beta-Actin 
 
Mouse Actin (clone C4) MP Biomedicals 
beta-Actin Rabbit Actin 21-33 Sigma Aldrich 
GPT2 Mouse sc-398383 Santa Cruz 
Biotechnology 
PC Rabbit HPA058765 Atlas Antibodies 
P62 Guinea Pig GP62_C Progen 
P-70S6K Rabbit CST2708 Cell signaling 
technology 
p-P70S6K (T389) Rabbit CST9234 Cell signaling 
technology 
4EBP1 Rabbit CST9644 Cell signaling 
technology 
mTOR Rabbit CST2972 Cell signaling 
technology 
p-mTOR (S2448) Rabbit CST2791 Cell signaling 
technology 
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Supplementary Figure 1 
 
Supplementary Figure 1: GPT2 is upregulated in basal breast cancer. A, Box plots 
showing GPT2 mRNA expression analysis of the TCGA dataset separated by molecular 
subtypes. Histograms showing GPT2 (B) and GPT1 (C) mRNA expression analysis of 41 breast 
cancer cell line dataset1, arrows indicating MCF7 and MDA-MB-468. D, qRT-PCR analysis of 
GPT1 and GPT2 expression in the MDA-MB-468 cell line. Graph shows expression of GPT1 
relative to GPT2. E, Percentage of labelled alanine pools in MDA-MB-468 and MCF7 cells 
24h post treatment with treated with 75 μM and 100 μM of GPT2 inhibitor β-chloro-L-alanine 
respectively with 30 min incubation with media supplemented with 13C-glucose, measured by 
GC-MS. Data are represented as mean ± SD, n=3 biological replicates unless stated otherwise. 
***P<0.001, ** P<0.01, * P<0.05, t-test.  
 
Supplementary Figure 2 
 
Supplementary Figure 2: Abrogation of GPT2 inhibits MDA-MB-468 cell growth. 
Analysis of GPT2 mRNA levels (A), GPT2 protein expression (B) and relative cell numbers 
(C) upon siRNA transfection of individual siRNAs or a pool (and corresponding control). Data 
are represented as mean ± SD, n=3 biological replicates unless stated otherwise. ***P<0.001, 
** P<0.01, * P<0.05, t-test.  
Supplementary Figure 3 
 
Supplementary Figure 3: Abrogation of GPT2 mildly affects MCF-7 cell growth. A, qRT-
PCR analysis of GPT2 mRNA expression and western blot analysis of GPT2 protein expression 
72h after transfection with a pooled siRNA targeting GPT2 (or corresponding non-targeting 
control). B, Relative cell numbers upon GPT2 knock-down. Relative extracellular alanine 
levels at different GPT2 inhibitor concentrations (C) or 72 h after treatment with 100 µM 
inhibitor (D). E, RPPA analysis of GPT2 protein expression 24h after treatment with 100 μM 
of GPT2 inhibitor β-chloro-L-alanine (or corresponding water control). F, Relative cell 
numbers treated with 100 µM of the GPT2 inhibitor β-chloro-L-alanine. G, Relative cell 
numbers of MDA-MB-468 and MCF7 72h after treatment with different concentrations of 
GPT2 inhibitor. Data are represented as mean ± SD, unless otherwise mentioned n=3 biological 
replicates.  ***P<0.001, t-test.  
Supplementary Figure 4:  
 
Supplementary Figure 4: Chemical or genetic inhibition of GPT2 does not affect 
glutamine uptake and TCA cycle intermediates in MCF7 cells. (a) Analysis of glutamine 
(UPLC) and glucose (GC-MS) consumption and lactate (GC-MS) secretion in MCF7 cells, 24h 
post treatment with GPT2 inhibitor (100 μM) (or corresponding water control), (b) GC-MS 
analysis of intracellular metabolites, 24h post treatment of MCF7 cells with GPT2 inhibitor 
(100 μM) (or corresponding water control), (c) GC-MS analysis of intracellular metabolites on 
the MDA-MB-468 WT or GPT2-KO clones. Data are represented as mean ± SD, n=3 biological 
replicates. ** P<0.01, * P<0.05, t-test. 
 
Supplementary Figure 5: 
 
Supplementary Figure 5: GPT2 inhibition rewires glucose metabolism. A, Total labelled 
metabolite pools in MDA-MB-468 cells 24h post treatment with GPT2 inhibitor (75 μM) and 
30 min incubation with media supplemented with 13C-glucose, measured by GC-MS. B, 
Percentage of labelled metabolite pools in MCF7 cells 24h post treatment with GPT2 inhibitor 
β-chloro-L-alanine (100 μM) and 30 min incubation with media supplemented with 13C-
glucose, measured by GC-MS. C, Total labelled metabolite pools in MCF7 cells 24h post 
treatment with GPT2 inhibitor β-chloro-L-alanine (100 μM) and 30 min incubation with 
media supplemented with 13C-glucose, measured by GC-MS. D, Relative MCF7 cell 
numbers 72h after transfection with siPC (or corresponding control) and treatment with GPT2 
inhibitor β-chloro-L-alanine (75 μM) (or corresponding water control) (left) qRT-PCR 
analysis of PC mRNA (n=1, 3 technical replicates) 72h after transfection in MCF7 cells 
(right). Data are represented as mean ± SD, n=3 biological replicates. ***P<0.001, ** 
P<0.01, * P<0.05 t-test.  
Supplementary Figure 6: 
 
Supplementary Figure 6: GPT2 protein expression correlates with high mTORC1 activity 
and low p62 levels in patients. Xenograph growth (A) and tumor weight (B) of MDA-MB-
468 WT and clone GPT2 KO2. C, GC-MS analysis of metabolite levels in WT and GPT2 KO2 
tumors. D, 4EBP1 hyper phosphorylated band quantification of experiment shown in Figure 5b 
and 5c. E, Correlation between protein expression of GPT2 and autophagy related proteins in 
all patients in the PiA cohort. Correlation coefficient (r) and significance were calculated using 
Pearsons‘ correlation test. *P<0.05, ***P<0.001 t-test.  
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